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Background: Preemptive analgesia has as its basic principle the administration of analgesics before the onset of 
painful stimuli, in order to reduce or prevent postoperative pain, but this question is little explored in implantology. 
Thus, this study was conducted in order to evaluate the clinical efficacy of ibuprofen in pain prevention after unit 
implant surgery. 
Material and Methods: For this triple-blind, parallel, placebo-controlled and randomized clinical trial, 54 insertion 
surgeries of unitary implants were performed. Two groups have received two different protocols 1 hour before sur-
gery: Ibuprofen group (IBU) 600 mg of ibuprofen; and (2) placebo group (maize starch). The intensity of the pain 
was evaluated through the visual analogue scale (VAS) in 6 times (1, 6, 12, 24, 48 and 72 hours after the surgery). 
Patients were instructed to take 750 mg of paracetamol as rescue medication, if necessary. The occurrence and the 
intensity of pain were analyzed by means of an analysis of variance ANOVA with repeated measurements using the 
general linear model procedure. 
Results: The IBU group had significantly lower VAS scores overall (IBU = 0.30, ± 0.57; placebo = 1.14, ± 1.07; 
p<0.001) and at all times in the intra, intergroup comparisons and time/group interaction than the placebo group 
(p< 0.001). The use of rescue medication was significantly lower and the postoperative time was longer in the IBU 
group compared to placebo (p = 0.002). 
Conclusions: The single use of ibuprofen was found to be significantly superior in reducing pain after unit implant 
surgery compared to placebo.
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Introduction
Pain is a factor hardly dissociated from dental treatment 
(1). Their presence or only the possibility of feeling 
it can trigger innumerable reactions such as fear and 
anxiety, which can directly interfere with the safety of 
looking for a particular treatment (2-4). In addition, the 
dental procedures that generate the greatest fear associa-
ted with the possibility of pain include surgical procedu-
res, particularly those of implantology (1).
The concept of preemptive analgesia (PA) to reduce the 
postoperative pain was based on a series of experimental 
animal studies (5), which demonstrated central nervous 
system plasticity and sensitization after nociception. The 
PA has as basic principle the administration of analgesics 
before the onset of painful stimuli, in order to reduce or 
prevent postoperative pain (hyperalgesia), as well as to 
reduce the analgesic dose required in the postoperative 
period when compared to the dose used alone, after the 
occurrence of the pain stimulus (1).
Three classes of analgesic drugs [blockages with lo-
cal anesthetics, non-steroidal anti-inflammatory drugs 
(NSAIDs) and opioids] have been used for this purpose 
alone or in combination (5,6).
Several studies have been conducted in PA, particularly 
in third molar extraction surgeries (7-12,) periodontal 
surgeries (13-15), and few studies in implant dentistry 
(1,16-18), with conflicting results. In addition, different 
types of drugs have been tested in PA (1,9,13-16) howe-
ver without a consensual definition of the best protocol 
regarding the drug, posology and period of exposure to 
the drug.
Studies have shown a high preference for the use of 
Ibuprofen in pain control related to dental problems or 
dental procedures (12,16,19) Ibuprofen, a name derived 
from the initials of isobutylphenyl propionic acid, is a 
drug in the group of NSAIDs which acts by non-selec-
tively inhibiting cyclooxygenase 1 and 2 thus avoiding 
the consequent formation of pro-inflammatory media-
tors by the arachidonic acid cascade (19).
In this sense, the hypothesis for this study was that 
individuals who receive PA with the use of ibuprofen 
(600 mg, oral) 1 hour before the implant surgery present 
lower postoperative pain in relation to individuals recei-
ving placebo medication.
Thus, the objective of this study was to evaluate and to 
compare by means of a randomized clinical trial, para-
llel-controlled and triple blind the efficacy of preemptive 
administration of Ibuprofen (600 mg oral) 1 hour before 
surgery for single insertion of implants osseointegrated 
in the control of postoperative pain.
Material and Methods
-Study sample
This study was conducted from November 2018 to May 
2019, in a private clinic of Implantology in the city of 
Belo Horizonte, Brazil. Fifty-four eligible individuals, 
both genders, non-smokers, aged 37 to 74 years were 
selected to participate in this randomized clinical trial, 
controlled, parallel and triple blind.
The nature of the study was previously explained to 
each patient, who signed a consent form, and this study 
was approved by the Ethics Committee in Human Re-
search of the Federal University of Minas Gerais, Brazil 
(83534618.5.0000.5149) and registered in Brazilian re-
gistry of clinical trials (ReBEC) under identifier RBR-
4B5DSG (www.ensaiosclinicos.gov.br).
The following inclusion criteria were adopted: 1) good 
systemic health status (ASA I or II); 2) absence of cu-
rrent pain or presence of any oral inflammatory process; 
3) without analgesics in the 3 weeks prior to the study; 
4) lack of continuous use of steroid and non-steroidal 
anti-inflammatory drugs; 5) need to install unitary im-
plants not concomitant with maxillary and mandibular 
exodontia; 6) implants of 3.75 mm in diameter with 11 
to 13 mm in length; 7) presence of compatible bone wi-
dth and height determined by tomographic examination 
(cone-bean computed tomography). The following were 
excluded: pregnant or lactating women, use of some 
type of medication that could affect the perception of 
pain, history of allergy or intolerance to the drugs (ibu-
profen and paracetamol) used in the research; and his-
tory of alcohol or drug abuse.
-Sample Calculation
Using statistical power analysis software R (software, 
R Foundation, Vienna, Austria), it was determined that 
25 patients per group would be required to achieve 80% 
of power at 95% of confidence interval (CI), assuming 
moderate to intense changes in pain score 24 hours after 
surgery in at least one group and non-normal distribution 
data (16). In order to compensate for possible data loss 
during the study, the number of individuals allocated per 
group was increased by 10%, with 27 patients per group.
Randomization
All patients involved in this study were selected throu-
gh a sequential non-probability method, that is, conse-
cutive cases were drawn for each eligible intervention 
using, alternatively, envelopes denominated group I 
and II in consultation prior to surgery. Randomization 
in the groups was performed by a sequential stratified 
randomization process that consisted of the use of 54 
opaque envelopes, where the identifications of the treat-
ment groups (groups I and II) were placed. The envelo-
pes were sealed and scrambled, and later numbered in 
sequential order. For each new entrant in the study, a 
subsequent numbering envelope was opened. The flow 
diagram is show in figure 1.
-Medications used
The following drugs were used in this research: Ibupro-
fen(Alivium ® Mantecorp Industry, São Paulo, Brazil) 
– tablets 600 mg, a placebo containing maize starch and 







Assessed for eligibility (n=127) 
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 ̈Not meeting inclusion criteria (n=60) 
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Lost to follow-up (give reasons) (n=0) 
Discontinued intervention (n=0) 
GROUP II= Allocated to intervention (n=27) 
 ̈Received allocated intervention (n=27) 
 ̈Did not receive allocated intervention (n=0) 
Analysed group II (n=27)  









Group Group I = IBUPROFEN 
(n=27) 
Group II = PLACEBO (n=27) 
 VAS (1,6,12,24,48,72 hours post 
surgery) 
Fig. 1: Flow Diagram.
Paracetamol(Tylenol ® - Johnson & Johnson, São José 
dos Campos, Brazil) - tablets 750 mg. All drugs used in 
the research were conditioned in white capsules, placed 
in bottles identified as group I or II medication by the 
researcher (G.M.P).
-Instructions for the study and collection of variables
All participants in consultation prior to surgery have re-
ceived detailed instructions for the correct form filling 
and visual analogue scale (VAS) for postoperative pain 
assessment. They were advised to contact the operator 
in case of any doubt. Thus, following randomization 
procedures, the individuals received a vial containing a 
medicine capsule from Group I or a medicine capsule 
from Group II, which should be ingested 1 hour before 
the surgical procedure. In addition, Paracetamol 750 mg 
tablets were made available to all individuals to be used 
as a rescue medication in case of pain. The use of rescue 
medication was at the discretion of the patient in case of 
pain. It is noteworthy that all patients registered in this 
consultation on mobile phones a reminder to take the 
drug 60 minutes before the scheduled time for surgery.
The following information was collected in this consul-
tation: age, gender, body mass index, educational level, 
family income expressed in minimum salaries, as well 
as additional information on health in general.
-Visual Analog Scale (VAS)
Participants have completed a visual analogue scale 
(VAS), where they indicated the presence and intensity 
of pain (20,21). This scale has 10 cm of lenght, subdi-
vided into five equal parts, where one end corresponds 
to no pain (0), and the other end to severe pain (10,22). 
The registry was completed by all participants at the fo-
llowing times: 1, 6, 12, 24, 48 and 72 hours post-surgery. 
In addition, in case of the necessity of the use of rescue 
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medication, the registration was made at the time of ta-
king the medication in relation to the time elapsed after 
the end of the surgery.
-Surgical Procedures
Surgical procedures were performed by a single opera-
tor (F.O.C.) through a mucoperiosteal flap where unitary 
implants (Titamax, external hexagon, Neodent, Paraná, 
Brazil) were inserted according to the manufacturer’s 
instruction. The individuals were anesthetized with a 
local infiltrative anesthetic (Prilocaine hydrochloride 30 
mg/ml) block using 2 to 4 anesthetic tubes at most. All 
surgical procedures were performed in up to 1 hour.
-Statistical analysis
The analyzes were performed blindly by a researcher 
(LOMC) continuing to assign the groups as groups I 
and II. The variables of interest were reported for des-
criptive measures (mean, standard deviation and CI) 
and analyzed using the chi-square test and t-test when 
appropriate. The perception of pain over time (VAS 1 
hour to 72 hours) between the groups (Placebo vs IBU) 
was analyzed separately by the Friedmam test (analysis 
of variance by ranks) and subsequently by means of a 
2-way analysis of variance ANOVA with measures re-
peated through general linear model procedure (GLM). 
Variables IBU (n=27) PLACEBO (n=27) P












































Time of surgery (minutes) * 49 ± 5.1 51 ± 4.2 0.328
Comparative analysis of the need for medication res-
cue for pain control and survival analysis for need of 
rescue were performed using the Manny-Whitney and 
Mantel-Cox tests, respectivaly. The data were analyzed 
using the statistical program (R software). Subsequently 
the analysis according to the initial knowledgeable in-
vestigator (G.M.P.) of the groups has revealed that group 
I used Ibuprofen (group IBU) and group II the capsule 
with maize starch (placebo group).
Results
The study has involved 54 non-smoking patients of 
both genders, with no significant differences in BMI, 
surgery time, anatomical position of the implants, so-
cioeconomic and cultural level among the IBU and 
placebo groups (Table 1). However, they have presen-
ted significant differences for age and gender, the IBU 
group consisted of 12 women and 15 men and the pla-
cebo group of 21 women and 6 men (p = 0.012). The 
mean age in the IBU group was 61.07 ± 8.01, while in 
the control group 55.63 ± 9.36 (p = 0.026) (Table 1). 
No major adverse effects (infections, major edemas or 
bleeding) and no side effects of the drugs were reported 
in both groups.
Table 1: Variables of interest*.
Teste t-Student (mean, standart desviation); **Chi-square test (n; %), †BMS= Brazilian Minimum salary, monthly 
(~300 american dollars).
J Clin Exp Dent. 2020;12(1):e71-8.                                                                                                                                                                                                    Preemptive analgesia and ibuprofen
e75
Table 2 and figure 2 shows the comparisons of the scores 
obtained by the VAS for pain according to the groups and 
times. Overall, the IBU group (VAS = 0.30, ± 0.57) had sig-





VAS 1H VAS 6H VAS 12H VAS 24H VAS 48H VAS 72H
Mean 0.30 0.15 0.41 0.44 0.44 0.19 0.16
s.d. ±0.57 ±0.36 ±0.57 ±0.57 ±0.69 ±0.80 ±0.47
Group Placebo
N=27
Mean 1.14 0.74 1.56 2.22 1.56 0.48 0.26
 s.d. ±1.07 ±1.05 ±1.36 ±1.34 ±1.12 ±0.84 ±0.71
Comparation 
intergroups*
<0.001 0.011 <0.001 <0.001 <0.001 0.050 0.734
Comparation Groups** <0.001
Comparation Times** <0.001
Group vs time** <0.001
Table 2: Comparison of the VAS variable for pain according to groups and times.
Friedman test (two-way analysis of variance by ranks)*; ANOVA; general linear model (GLM) **; s.d.=standart desviation.
	
Fig. 2: Boxplot distribuition VAS scores in time by groups.
= 1.14, ± 1.07) (p<0.001). In addition, the IBU group also 
presented values significantly lower than those reported in 
the control group at all times in the intragroup, intergroup 
comparisons and in time and group interaction (p <0.001). 
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Regarding the need to use of the rescue medication to 
control postoperative pain, the IBU group has used sig-
nificantly less rescue than that observed in the placebo 
group (Table 3; Placebo> IBU; p = 0.002).














Inferior limit Upper limit
IBU 45.24 ±6.51 32.47 58.01
Placebo 18.85 ±4.37 10.28 27.42
p 0.007
sent a survival analysis of the need to use of the rescue 
medication, i.e., time elapsed from the first rescue event 
(mean in hours). In the placebo group the elapsed time 
was significantly lower (18.85 ± 4.37 hours) in relation 
to the IBU group (45.24, ± 6.51 hours, p = 0.007).
Discussion 
In this study, the use of ibuprofen 1 hour prior to the 
surgical procedures for insertion of unitary implants has 
revealed, overall, a significant effect on reduction of 
postoperative pain, at all times evaluated, less need for 
rescue medication, as well as a longer time for the occu-
rrence of the rescue event in relation to the individuals 
with the use of placebo medication. Thus our hypothesis 
of its beneficial effect on the reduction of postoperative 
pain was affirmative.
Theoretically, PA is defined as an antinociceptive treat-
ment (5), which aims to prevent central and peripheral 
sensitization, reducing or preventing the amplification of 
postoperative pain. It is believed that this strategy gua-
Table 3: Comparative analysis of the need for medication 
rescue for pain control.
Mann-Witney Test ; s.d.=standart desviation.
Table 4: Survival analysis for need of rescue.
Equality test (Mantel-Cox).
Fig. 3: Survival analysis for need of rescue.
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rantees a reduction in the consumption of analgesics in 
the postoperative period, providing comfort and redu-
cing the recovery time of the patient (5,23).
In our study, the IBU and placebo groups differed sig-
nificantly in age and gender, without differences in re-
lation to the other variables studied, such as anatomical 
position of the implants, surgery time, BMI, family in-
come and socioeconomic level.
Analyzing the plurality of factors that may interfere with 
perceived pain (4), the absence of differences in almost 
all variables surveyed between the groups in our study 
seems to contribute to the validation of our findings. It 
is known that the level of pain correlated with physical 
stimuli as a result of dental interventions is difficult to 
determine, since perceived pain depends on an indivi-
dual threshold and is influenced by emotional, cognitive 
and cultural factors (24-27).
In a review about orofacial pain (25) the data were not 
conclusive about the role of gender and age influencing 
pain. It has been reported that women are more willing 
to report pain than men, and that this perception appears 
to be associated at the pain threshold with respect to heat 
tolerance. However, after controlling the willingness to 
report pain, the difference in the thermal pain threshold 
was no longer statistically significant. In addition, a 
study on predictors of pain in dental treatment has repor-
ted no differences in pain reported in relation to gender 
and age (24).
Future research needs to elucidate the influence of socio 
cultural, environmental, and psychological factors on 
pain as well as the effects of sex on factors that pro-
tect against the development of pain or that prevent pain 
from becoming debilitating (28). Thus, we consider that 
due to the randomization process and the conflicting 
pain data regarding gender and age, we do not believe in 
the interference of this variable in our results.
Several studies have been conducted in PA in dentistry. 
Most studies focus on third molar extraction surgeries 
(7-10,12,28) followed by periodontal surgeries (13-15) 
and  studies on implantology (1,16-18).
Moreover, in almost all different procedures using PA, 
the results are conflicting. In addition, studies with di-
fferent types of drugs have been tested in PA but without 
a consensual definition of the best protocol for the drug, 
posology and period of exposure to the drug. Thus, the-
re is a tendency in PA to test steroid and non-steroidal 
anti-inflammatory drugs with only one study testing the 
use of ibuprofen.
In a systematic review (29) it was verified that several 
clinical trials were conducted seeking to prove the effi-
cacy of PA in the clinical dental practice, however, they 
exhibited controversial results. According to Kissin (3) 
it is not possible to detect a preemptive effect in com-
parative studies of groups in which the analgesic is ad-
ministered only in the pre-incisional and post-incisional 
period, due to the complexity in the central sensitization 
mechanisms and the technical difficulties for the studies, 
considering it necessary the pre, trans and postoperati-
ve analgesic regimen. However, exploring its effects at 
different time intervals may bring further clarification 
of its effectiveness. In this context, this study has sear-
ched for this information in periods ranging from 1 to 72 
hours, as well as the additional need for rescue medica-
tion for pain control.
Additionally, in our findings, ibuprofen has proven to be 
very effective in reducing pain in the immediate posto-
perative period from 1 to 6 hours compared to placebo, 
significantly reducing the need for rescue medication 
and increasing the time required for rescue medication, 
thus according to the theoretical foundations of PA this 
initial reduction is very important because it has a posi-
tive effect on reducing pain at subsequent intervals of 
time (1,5,23).
In this context, our finding is supported by a systema-
tic review (29) of the oral kinetics of oral ibuprofen (30 
studies evaluating 1,015 individuals) which showed that 
mean maximum plasma concentrations of fast acting 
formulations occurred within 50 minutes (29-35 minu-
tes for arginine, lysine and sodium salts) compared to 
90 minutes for standard formulations. Initial rapid re-
duction of pain intensity was also associated with redu-
ced need for remedies. Additionally, the ibuprofen by 
inhibiting the production of prostaglandins, it leaves the 
gastric mucosa less protected against acidity, being its 
therapeutic efficacy easily seen overcoming the severity 
of its side effects (19).
Another point to be discussed refers to the extent and 
numbers of implants inserted in the surgical procedure. 
Low pain scores are related to implant surgeries and ac-
cording to Kim et al. (27) pain and anxiety scores are 
proportional to the number of implants inserted and the 
length of the surgical procedure. However, regarding 
these questions, our study presents the advantages of 
standardization of insertion of only one implant, with 
a single operator and similar surgery time between the 
groups.
The present study may be considered as a good starting 
point for future studies aimed at providing additional 
information on the use of ibuprofen in PA in implant 
surgeries. However, prospective multicentric studies, in 
different populations, with different surgical and dosing 
protocols, are necessary to confirm these findings and to 
establish a beneficial protocol for the control of pain in 
dental implant surgeries.
The present study demonstrated that the use of ibuprofen 
1 hour before to the surgical procedures for insertion of 
unitary implants has revealed a significant effect on the 
reduction of postoperative pain overall at all evaluated 
times has shown less need for the use of rescue medi-
cation and, when necessary, the time of use has been 
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shorter when compared to individuals on placebo. Thus, 
its use can be considered a beneficial adjuvant for the 
control of postoperative pain in dental implant surgeries.
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